EntreMed announces issuance of patent for clinical-stage compound, 2-methoxyestradiol

[News]

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced the issuance of a U.S. patent covering methods of treatment and formulations for its clinical-stage compound, 2-methoxyestradiol.

More... (http://www.news-medical.net/news/20130503/EntreMed-announces-issuance-of-patent-for-clinical-stage-compound-2-methoxyestradiol.aspx)